Table 1.

PICO indicators and criteria for scoping review.

PICO/Indicator	Criteria
Study design	Published qualitative and quantitative data related to blood pressure and blood sugar assessment from study designs-case series, cross-sectional studies, cohort studies, RCTs, pilot trials, screening costing and economic evaluation, health technology assessment of diabetes and hypertension screening
Population	Clinical, co-morbid or healthy population aged 18 years or above who have undergone any type of screening or assessed in survey or surveillance in Nepal
Intervention	Screening, surveillance or survey
Comparator	Having control or standard treatment or placebo or no comparator
Outcome	Any of the followings (Qualitative and/or Quantitative finding) 1. From screening: any of true positive rate (TPR), true negative rate (TNR), false positive rate (FPR), false negative rate (FNR), sensitivity, specificity, yield, positive predictive value (PPV), negative predictive value (NPV). 2. Ratio of screened +ve to screened -ve (among the total visited to surveillance center) 3. From Screening, Survey or Surveillance: Number of subjects needed to screen or survey for one case of DM or HTN 4. Costing per case identifying 5. Costing per individual screening 6. Incremental cost-effectiveness ratio (ICER) 7. Proportion of hypertension (95% CI) 8. Proportion of diabetes mellitus (95% CI) 9. Proportion of hypertension awareness among the hypertensives 10. Proportion of diabetes awareness among the diabetics 11. Proportion of taking medication among the hypertensives 12. Proportion taking medicines among the diabetics 13. Proportion of controlled BP among the hypertensives 14. Proportion of controlled sugar among the diabetics 15. Health technology assessment (HTA) 16. Ethics in screening of DM and HTN 17. Quality of life (QoL) of screening of DM and HTN 18. Willingness to pay (WTP) and cost of screening of DM and HTN 19. Capacity to pay (CTP) of screening of DM and HTN
Published duration	Last 6 years (2016–2021)